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Abstract
 .The regulation of Phospholipase C PLC d activity remains obscure. These studies show that PLCd activity is1
 .  .significantly enhanced by both guanosine thiotriphosphate GTPg S and Clostridium botulinum exoenzyme C3 C3 but not
by aluminium fluoride. C3 ADP ribosylated a 21-kDa protein in the PLCd preparation and Western blotting identified1
rhoA in these samples. RhoA acts as an inhibitory modulator of PLCd activity. q 1998 Elsevier Science B.V. All rights
reserved.
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Phosphoinositide-specific phospholipase C is re-
sponsible for the hydrolysis of phosphatidylinositol
 .4,5-bisphosphate PIP into inositol 1,4,5-tri-2
 .  .sphosphate IP and 1,2-diacylglycerol DAG . The3
products of this reaction are both key second messen-
gers playing a central role in a number of signalling
pathways. IP has been shown to bind to receptors on3
the sarcoplasmic reticulum and promote release of
2q w xCa from intracellular stores 1 . DAG, on the other
hand, remains membrane bound and causes activation
w xof protein kinase C 2 . Phosphoinositide kinases and
their products have also been implicated in the regu-
lation of the actin cytoskeleton, with PIP having2
been shown to bind both the actin regulatory proteins
profilin and gelsolin, and promote filament polymeri-
w xsation 3 .
) Corresponding author. Fax: q44-171-886-6145; E-mail:
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The phosphoinositide-specific family of phospholi-
pase C enzymes consist of three isoforms termed b ,
g and d PLCa is now thought to be a breakdown
w x.product of other isoforms 4 . All PLC isoforms
contain the X and Y regions of sequence homology
essential for catalytic activity and all recognise phos-
 .phatidylinositol PI , phosphatidylinositol 4-phos-
 . 2qphate PIP and PIP and carry out the Ca -depen-2
dent hydrolysis of these inositol lipids, they are,
w xhowever, differentially regulated and expressed 5 .
PLCb , of which there are four known isoenzymes
 .PLCb –b has been demonstrated to be regulated1 4
w xby heterotrimeric G-proteins 5–7 . PLCb , b and1 3
b are regulated by the a subunits of the pertussis4
toxin-insensitive G family of heterotrimeric GTP-q
w xbinding proteins 8–11 , PLCb however, is largely2
w xregulated by G-protein bg subunits 12 . PLCg ,
comprising PLCg and g , contains two SH2 and an1 2
SH3 domain and is regulated by tyrosine phosphory-
lation following binding to either growth factor acti-
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vated receptor tyrosine kinases such as platelet de-
 .rived growth factor PDGF and epidermal growth
w xfactor 13,14 , or by non-receptor linked tyrosine
w xkinases of the src family 15 . PLCd , with a molecu-
lar mass of approximately 85 kDa, is probably the
w xearliest isoform of PLC in evolutionary terms 16
w xand the most widely expressed 17,18 . However, its
mechanism of regulation has remained obscure. PLCd
does not contain src homology domains, but has been
shown to contain the plekstrin homology and C2
domains which tether the enzyme to the membrane
w x19 , and are implicated in the strong binding to
phospholipids, particularly PIP , which has been2
w xdemonstrated for this isoenzyme 20,21 . In addition
to its calcium dependence, the enzyme has also been
w xreported to be activated by phosphatidic acid 22 and
w xinactivated by sphingomyelin 23 and most recently
to be an effector in the Gha transglutaminase path-
w xway 24 .
Studies of the mechanism of regulation of PLCd
activity have been hampered by an inability to study
w xPLCd in isolation from other forms of PLC 25 , the
apparent cross-talk between PLC isoforms in terms of
w xregulation of activity 26,27 and by the absence of
w xregulatory cofactors in reconstitution studies 28 . We
have overcome this problem by separating PLC iso-
forms, in conjunction with their regulatory proteins,
from bovine aorta using affinity chromatography
techniques. This has allowed us to both isolate an
active PLC preparation, which is immunoreactive to
PLCd only, and to study its regulation.1
Bovine aortae were cleared of fat, cut into small
pieces and incubated at 378C in a solution of collage-
 . nase 400 mgrml in PSS NaCl 119 mM, KCl 4.7
mM, CaCl 2.5 mM, MgSO 1.17 mM, NaHCO 252 4 3
mM, KH PO 1.18 nM, EDTA 26 nM and glucose2 4
.5.5 mM for 1 h and the adventitia removed. The
tissue was then minced and homogenised in 2 vol-
umes of ice-cold buffer 20 mM Tris–HCl: pH 7.5;
50 mM NaCl; 250 mM sucrose; 1 mM dithiothreitol
w xDTT ; 1 mM EDTA; 5 mM MgCl ; 176 mgrml2
PMSF; 1 mgrml leupeptin; 1 mgrml aprotinin; 0.7
.mgrml pepstatin A . Cell debris was removed by
 .centrifugation 10 min, 3000 rpm , the supernatant
was filtered through cheesecloth, centrifuged at
17,000 rpm for 2 h at 48C and equilibrated overnight
in 15 volumes of chromatography running buffer 10
mM Tris–HCl: pH 7.5, 50 mM NaCl, 1 mM DTT, 1
mM EDTA containing 5% glycerol, 176 mgrml
PMSF, 1 mgrml leupeptin, 1 mgrml aprotinin and
.0.7 mgrml pepstatin A prior to being loaded onto
Q-sepharose. Bovine aortic cytosol was eluted from
Q-sepharose in 5 ml fractions using a linear sodium
 .chloride gradient 50–550 mM and the protein con-
tent and PLC activity of every fifth fraction was
determined. PLC activity was measured using a
w xmethod based on that described by Waldo et al. 29 ,
w3 xand using H -PI as a substrate. This resulted in four
 .distinct peaks of PI-PLC activity P1–P4 Fig. 1A .
Fractions constituting P2 were pooled, concentrated
by ultrafiltration and equilibrated with running buffer
prior to loading onto heparin-agarose. Fractions eluted
from this column with a linear salt gradient 50–550
.mM gave a single peak of PLC activity which
 .occurred between fractions 85 and 120 Fig. 1B .
Immunological analysis of the fractions eluted from
heparin-agarose demonstrated the presence of PLCd1
 .in these samples 1c . Neither PLCb nor PLCg1 1
were detected in these fractions by Western blotting.
The PLC family of isoenzymes is a rapidly expand-
ing group of proteins, with this in mind the PI-PLC
activity of these samples was measured following
removal of the PLCd isoenzyme by immunoprecip-1
itation. Fractions from heparin-agarose chromatogra-
phy containing PLC activity were pooled and 250 mg
protein was immunoprecipitated at 48C for 3 h with a
 .monoclonal antibody to PLCd TCS following pre-1
clearing with albumin agarose.
Immunoprecipitates were captured using protein
 .A-agarose Oncogene Science in the manner de-
w xscribed by Abedi et al. 30 . This resulted in a
 .reduction in PLC activity of 89"3% ns3 indicat-
ing that the sample is not significantly contaminated
with any other isoform of PLC known or unknown.
In order to determine whether GTP-binding pro-
teins have a role in the regulation of PLCd activity1
samples were preincubated for 30 min at 378C with
10–100 mM GTPg S, a non-hydrolysable analogue of
GTP, and the PLCd activity measured. The resting1
PLC activity was consistently and significantly en-
hanced by the addition of GTPg S, control 860"268
cpm vs. 10 mM GTPg S 1182"274, ns7, ps0.01;
control 624"206 cpm vs. 100 mM GTPg S 1117"
.263, ns9, p-0.01 , and this was maintained under
low magnesium conditions 0.5 mM—data not
.  .shown . NaF 10 mM produced a small increase in
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Fig. 1. Isolation of PLCd fraction from bovine aortic cytosol.1
 .A Measurement of PI-PLC activity from Q-sepharose gave four
peaks of activity: P1s fractions 75–95; P2s fractions 175–200;
 .P3s fractions 210–240; P4s fractions 260–275. B Fractions
constituting P2 were pooled and loaded onto heparin-agarose.
Fractions eluted from this column gave a single peak of PLC
 .activity; fractions 85–100. Representative example of ns11. C
Demonstration of PLCd in increasing quantities of pooled1
 .fractions 85–100 from heparin-agarose; representative example
of ns6.
PLCd activity and this activity was not affected by1
 .the presence of deferoxamine 0.5 mM , a chelator of
aluminium, suggesting that this may be a non-specific
response to NaF and unrelated to activation of het-
erotrimeric G-proteins. Deferoxamine itself had no
effect on PLCd activity. PLCd activity was not1 1
stimulated by 100 mM ATPg S 102"3% of resting
. activity, ns3 or by 100 mM GDPb S 90"9% of
.resting activity, ns3 . Overall these results are
strongly suggestive of bovine aortic PLCd activity1
being regulated by a GTP-binding protein and that
this GTP-binding protein is a member of the small
GTPase superfamily. To confirm that a GTP-binding
protein was co-eluting with the PLCd fraction the1
GTP-binding of column eluates was measured using
w35 xS -GTPg S. Briefly 50 ml of sample was incubated
with 150 ml of reaction buffer containing HEPES 20
.  .  .mM, pH8 , NaCl 100 mM , MgCl 20 mM , GTPg S2
 . w35 x  .1 mM and S -GTPg S 1 mCi for 1 h at 378C.
Samples were then placed on ice prior to being
harvested on glass fibre filters and counted in a
scintillation counter in the manner described by
w xSternweis and Robishaw 31 . These results demon-
w35 xstrated that the S -GTPg S binding profile gener-
ated by the elution of P2 from heparin-agarose corre-
 .lated well with that of PLCd activity Fig. 2A . The1
presence of functional GTP-binding proteins com-
w35 xplexed with PLCd was investigated by S -GTPg S1
binding to immunoprecipitated PLCd run on a 12%1
w xpolyacrylamide gel using an overlay method 32 .
The results of these experiments demonstrated that
PLCd is consistently complexed with functional1
 .GTP-binding proteins Fig. 2B .
C3 was used in order to investigate which mem-
 .ber s of the monomeric GTPase superfamily might
be involved in the regulation of PLCd activity. This1
exoenzyme has been demonstrated to selectively
w xADP-ribosylate the rho small GTPases 33 . Ribosy-
lation of rho by C3 is approximately 100-fold more
efficient than rac and 400-fold more efficient than
CDC42Hs. Hence, C3 should be specific for rhoGT-
w xPases at the concentrations used in these assays 34 .
Preincubation of the PLCd sample with C3 and1
NAD for 1 h resulted in a significant increase in
resting activity control 399"166 cpm vs. C3 537"
.183, ns11, p-0.001 whereas, incubation with
NAD alone had no effect on PLC activity suggesting
that a rho GTPase is acting as an inhibitor of PLCd1
 .activity. Similarly, samples containing PLCd 8 mg1
incubated for 90 min at 378C in the presence of
 . w32 x  .exoenzyme C3 20 mgrml , P -NAD 7.5 mM ,
 .and GDP 100 mM in a final volume of 20 ml and
run on a 12% SDS-polyacrylamide gel clearly
demonstrated the presence of a 21-kDa ADP-ribosy-
lated protein consistent with the presence of rho data
.not shown . Western blotting has identified rhoA in
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 .Fig. 2. Relationship between GTPg S and PLCd . A Protein1
concentration, GTP-binding and PLC activity of fractions eluted
from heparin-agarose columns were measured in quadruplicate
and the results, expressed as mean cpm, or absorbance at 595 nm
 .were overlaid. PI-PLC activity v gave a single peak of activity
w35 x  .over the fraction range 95–110. S -GTPg S binding ‘ also
gave a peak of activity over the fraction range 95–105. Ab-
sorbance at 595 nm, however, demonstrated two peaks of protein
 .l over the fraction ranges 0–20 and 50–65. Data shown are a
 .representative example of three separate experiments. B
Demonstration of GTP-binding proteins, approximate molecular
weights 21, 43, 72 kDa, consistently complexed with immunopre-
cipitated PLCd . Data shown are a representative example of1
ns4 bovine aortae.
all of the immunoprecipitated PLCd samples1
 .Fig. 3 .
The idea of PLCd being regulated by GTP-bind-
ing proteins is one which has increasing support
w x24,25,35,36 , and there is growing evidence to sug-
gest that this regulation need not occur through het-
w xerotrimeric G-proteins 24,35 . The interaction of PLC
with small GTP-binding proteins has been implied by
w xa number of reports 24,28,36 indeed Homma and
Emori isolated a 122-kDa protein with both rhoGAP
w xand PLCd stimulatory activity 28 . This contrasts1
with data from studies examining the activation of
phospholipase D by rho which reported that C3 had
w xno effect on PLC activity 37 . These studies how-
ever, were concerned with total PLC activity in fi-
broblasts and made no distinction between the quan-
tity and number of isoforms present in the cells.
PLCd activity can be stimulated by both GTPg S1
and C3 suggesting that it may be under dual regula-
tion by GTP-binding proteins of a stimulatory and an
w xinhibitory nature. The work of Feng et al. 24 has
shown that PLCd can be stimulated by Gh a novel1
heterodimeric GTP-binding protein and we have
identified a 72-kDa GTP-binding protein which is
consistently complexed with PLCd . The data ob-1
tained in this study indicate that monomeric GTP-bi-
nding proteins also have a role in the regulation of
PLCd activity; 21-kDa GTPg S-binding protein is1
consistently complexed with immunoprecipitated
PLCd , incubation of the PLCd sample with C31 1
results in the ADP-ribosylation of a 21-kDa protein
and Western blotting has identified rhoA. We pro-
pose that rhoA exerts a negative modulatory influ-
ence on aortic PLCd activity; release from this1
Fig. 3. Identification of rhoA. PLCd was immunoprecipitated1
from the partially purified enzyme obtained from heparin-agarose
chromatography and run on a 10% SDS-polyacrylamide gel prior
to transfer onto nitrocellulose. The membrane was probed with a
polyclonal antibody to rhoA at 1:100 and visualised by ECL.
This figure shows the results obtained from bovine aorta 16 and
is a representative example of ns3.
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negative influence, through inhibition of rhoA by C3,
results in a significant increase in aortic PLCd activ-1
ity.
The role of small GTPases is continually being
revised and remodelled as new substrates for these
proteins are identified. However, it is clear that these
proteins play a major role in the organisation of the
w xactin cytoskeleton and cell motility 38 .
The mechanism by which rho proteins effect their
control on actin organisation is unclear although both
rac and rho have been demonstrated to be involved in
w xthe regulation of PIP synthesis 39,40 . Calcium has2
long been known to be a regulator of the dynamic
w xorganisation of actin filaments 41 and calcium mo-
bilisation can be initiated by PLC. Our data suggest
that modulation of PLCd activity may be an addi-1
tional mechanism by which small GTPases regulate
cellular functions.
We would like to thank Professor Sir David
Weatherall for his moral and financial support through
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